873948-11-9

Upstream product

• 530441-95-3 (R)-1-(1-(bromomethoxy)ethyl)-3,5-bis(trifluoromethyl)benzene 
• 552293-34-2 benzyl (2S)-2-({(1-R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl)-2-phenyl-3,4-dihydropyridine-1(2h)-carboxylate 

Downstream Products

• 867045-65-6 C₃₄H₃₄F₆N₂O₇ 
• 867045-66-7 C₃₄H₃₄F₆N₂O₇ 
• 867045-67-8 C₄₇H₅₀F₆N₂O₇ 
• 873947-63-8 benzyl (2S)-2-({(1R)-1-[3,5-bis(tri-fluoro-methyl)-phenyl]ethoxy}-methyl)-5-nitro-2-phenylpiperidine-1-carboxylate 

Relevant academic research and scientific papers

Conformation of gem-disubstituted alkylarylpiperidines and their implication in design and synthesis of a conformationally-rigidified NK 1 antagonist

Piperidines are ubiquitous in pharmaceuticals and bioactive natural products. Understanding the structural and functional properties of piperidines plays a key role in drug design and development. This Letter reported studies of conformation of a set of g

PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE COMPOUNDS

This application discloses a novel process to synthesize 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds, which may be used, for example, as NK-1 inhibitor compounds in pharmaceutical preparations.

BRIDGED RING NK1 ANTAGONISTS

A compound having the general structure shown in Formula (I): or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or di

FUSED RING NK1 ANTAGONISTS

A compound having the general structure shown in Formula (1) or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or dis